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103Noncorticosteroid
Immunosuppression
Limits Myocardial Damage
and Contractile Dysfunction
in Eosinophilic Granulomatosis
With Polyangiitis
(Churg-Strauss Syndrome)Eosinophilic granulomatosis with polyangiitis (EGPA)
(Churg-Strauss syndrome) is a rare, systemic, small- to
medium-sized vessel necrotizing vasculitis. The dis-
ease is characterized by common cardiac involvement,
which remains the major determinant of mortality (1).
Glucocorticoids and noncorticosteroid immunosup-
pressants are the cornerstones of therapy for this
disease; they inhibit the inﬂammatory process, pre-
vent organ damage, enhance survival, and reduce
the relapse rate. Glucocorticoids are the ﬁrst-line
agents in all patients with EGPA, whereas adjunctive
noncorticosteroid immunosuppressants are reserved
only for the most severe, life-threatening disease. To
date, the impact of noncorticosteroid immunosup-
pression on cardiac involvement in patients with
EGPA is poorly deﬁned and it remains unknown
whether such therapy can prevent heart damage.
Therefore, we hypothesized that the addition of non-
corticosteroid immunosuppressants to glucocorti-
coids may effectively limit myocardial damage and
contractile dysfunction in patients with EGPA.
Of the 65 patients with EGPA diagnosed and treated
at 4 tertiary centers from 1990 to 2013, identiﬁed in the
Vasculitis Registry of Jagiellonian University Medical
College, 51 patients with clinical remission (Birmingham
Vasculitis Activity Score ¼ 0 in last 3 months), complete
medical data, no severe valve dysfunction, and no
contraindication to magnetic resonance and/or gadolin-
ium contrast were enrolled in this study. Baseline
(demographic, clinical, laboratory, transthoracic echo-
cardiography) data on disease presentation and
course as well as therapeutic data on month-by-month
treatment were retrospectively collected. All patients
were scheduled for follow-up, including cardiacmagnetic
resonance to assess left ventricular ejection fraction
(LVEF) and myocardial damage depicted by late gado-
linium enhancement (LVLGE). Adverse cardiac events
were deﬁned as cardiac death and/or hospitalization due
to decompensated heart failure.
At diagnosis, 15 (29%) patients demonstrated car-
diac involvement. In addition at diagnosis, 49 (96%),
28 (55%), 28 (55%), 9 (18%), and 8 (16%) presented withlung, peripheral nervous system, skin, gastrointestinal
tract, and kidney involvement, respectively. Of those
with heart involvement, all patients presented with
heart failure, 2 patients had suspected acute coronary
syndrome with obstructive coronary atherosclerosis
excluded by coronary angiography, 1 patient had
sudden cardiac arrest with successful resuscitation,
5 patients had myocarditis, 4 patients had peri-
myocarditis, and 1 patient had pericarditis. Coronary
angiography was normal in all subjects with myocar-
ditis or perimyocarditis. Baseline transthoracic echo-
cardiography at diagnosis showed an LVEF of 56.1 
12.9%, and 13 (25%) patients had an LVEF <50%. At
diagnosis, all patients received glucocorticoids; 18
(35%) patients received additional noncorticosteroid
immunosuppression (16 patients received cyclophos-
phamide, 1 patient received methotrexate, and 1
patient received cyclosporine). During the disease
course, 21 (41%) patients experienced clinical re-
lapse(s). Because of relapse, 6 (12%) patients received
an additional noncorticosteroid immunosuppressant
(3 patients received cyclophosphamide, 2 patients
received azathioprine, and 1 patient received metho-
trexate). During disease course, 28 (55%) patients
received angiotensin-converting enzyme inhibitors,
25 (49%) patients received beta-blockers, 7 (14%) pa-
tients received mineralocorticoid receptor antago-
nists, 1 (2%) patient received an angiotensin receptor
blocker, and 1 (2%) patient received a calcium blocker.
At follow-up, all patients received low-dose glucocor-
ticoids, 7 patients (14%) received cyclophosphamide,
3 (6%) patients received azathioprine, and 1 (2%)
patient received methotrexate.
Follow-up was performed 39.2  38.7 months after
EGPAwas diagnosed. At follow-up, all patients were in
clinical remission, 29 (57%) patients had cardiac
involvement, 25 (49%) patients had heart failure, and
none had symptoms of angina. At follow-up, 49 (96%),
30 (59%), 28 (55%), 14 (27%), 10 (20%), and 4 (8%) had
history of lung, peripheral nervous system, skin,
kidney, gastrointestinal tract, and central nervous
system involvement, respectively. After diagnosis of
EGPA, noncorticosteroid immunosuppressants were
administered for 8.2  13.1 months, representing 25.6
 33.2% of disease duration. No patients died after
diagnosis, but 10 (20%) patients were hospitalized due
to decompensated heart failure. When comparing
subjects in whom noncorticosteroid immunosuppres-
sants were and were not initiated at diagnosis, the
latter more frequently presented with new onset or
progression (increase in New York Heart Association
functional class $1) of heart failure (1 [6%] vs.
12 [36%]; p ¼ 0.02) and required hospitalization due
to decompensated heart failure (0 [0%] vs. 10 [30%];
TABLE 1 Study Group Characteristics and Unadjusted Predictors of Left Ventricular Myocardial Damage (Late Gadolinium Enhancement) and Systolic Dysfunction (Ejection Fraction <50%) at Follow-Up
Parameter
All Patients
(n ¼ 51)
Left Ventricular Myocardial Damage at Follow-Up Left Ventricular Systolic Dysfunction at Follow-Up
Present (n ¼ 29) / Absent (n ¼ 22) OR (95% CI) Present (n ¼ 22) / Absent (n ¼ 29) OR (95% CI)
Baseline
Male 15 (29) 8 (28)/7 (32) 0.82 (0.24–2.74) 5 (23)/10 (34) 0.56 (0.16–1.97)
Age at diagnosis, yrs 41.2  14.8 39.8  14.5/43.1  15.3 0.99 (0.94–1.02) 37.9  11.9/43.7  16.4 0.97 (0.93–1.01)
Five-factor score at diagnosis >0 19 (37) 14 (48)/5 (23) 3.17 (0.92–10.90) 11 (50)/8 (28) 2.63 (0.82–8.43)
Heart failure at diagnosis 15 (29) 13 (45)/2 (9)* 8.13 (1.60–41.36)* 11 (50)/4 (14)* 6.25 (1.63–24.02)*
NYHA functional class at diagnosis, none/1/2/3/4 36/3/5/5/2 16/2/4/5/2 / 20/1/1/0/0 1.93 (1.03–3.62)* 11/1/3/5/2 / 25/2/2/0/0* 2.01 (1.15–3.53)*
Heart involved† at diagnosis 15 (29) 13 (45)/2 (9)* 8.13 (1.60–41.36)* 11 (50)/4 (14)* 6.25 (1.63–24.02)*
LVEF <50% at diagnosis 13 (25) 12 (41)/1 (5)* 14.82 (1.75–125.73)* 11 (50)/2 (7)* 13.50 (2.56–71.13)*
History of myocarditis 13 (25) 12 (41)/1 (5)* 14.82 (1.75–125.73)* 9 (41)/4 (14)* 4.33 (1.12–16.78)*
History of pericarditis 13 (25) 11 (38)/2 (9)* 6.11 (1.19–31.37)* 8 (36)/5 (17) 2.74 (0.75–10.04)
ANCA present 11 (22) 4 (14)/7 (32) 0.34 (0.09–1.37) 2 (9)/9 (31) 0.22 (0.04–1.16)
Maximum blood eosinophil count, 102 cells/ml 78.0  47.1 88.3  47.9/64.4  43.3 1.01 (1.00–1.03) 91.8  52.7/67.5  40.2 1.01 (0.99–1.03)
Medical therapy
Noncorticosteroid immunosuppressant
Not introduced 27 (53) 19 (66)/8 (36) 3.33 (1.04–10.59)* 16 (73)/11 (38)* 4.36 (1.31–14.51)*
Not introduced at diagnosis 33 (65) 24 (83)/9 (41)* 6.93 (1.92–25.06)* 19 (86)/14 (48)* 6.79 (1.64–28.04)*
Duration of therapy, months 0.0 (0.0–10.0) 0.0 (0.0–9.3)/6.5 (0.0–18.0) 0.95 (0.90–1.00)* 0.0 (0.0–13.6)/6.0 (0.0–17.3) 0.95 (0.89–1.01)
Therapy discontinuity index‡, % 100.0 (44.4–100.0) 100.0 (80.6–100.0)/ 57.7 (26.1–100.0)* 1.03 (1.01–1.05)* 100.0 (86.4–100.0)/64.3 (31.5–100.0)* 1.03 (1.01–1.06)*
Cyclophosphamide
Not introduced 32 (63) 21 (72)/11 (50) 2.63 (0.82–8.43) 17 (77)/15 (52) 3.17 (0.92–10.91)
Not introduced at diagnosis 35 (69) 24 (83)/11 (50)* 4.80 (1.34–17.19)* 19 (86)/16 (55)* 5.15 (1.24–21.30)*
Duration of therapy, months 0.0 (0.0–6.0) 0.0 (0.0–5.0)/0.0 (0.0–12.0) 0.94 (0.88–1.01) 0.0 (0.0–0.0)/0.0 (0.0–9.3) 0.95 (0.87–1.03)
Therapy discontinuity index‡, % 100.0 (78.8–100.0) 100.0 (87.8–100.0)/100.0 (44.4–100.0) 1.02 (1.00–1.05)* 100.0 (100.0–100.0)/100.0 (45.7–100.0) 1.03 (1.00–1.06)*
Corticosteroids
Introduced 51 (100) 29 (100)/22 (100) — 22 (100)/29 (100) —
Daily dose§ at remission, mg 7.1  2.2 6.8  2.2/7.5  2.2 0.88 (0.68–1.13) 7.0  2.4/7.2  2.0 0.96 (0.75–1.25)
Cardiovascular agents
Beta-blocker 25 (49) 18 (62)/7 (32) 3.04 (0.95–9.71) 14 (64)/11 (38) 2.36 (0.76–7.34)
Angiotensin-converting enzyme inhibitor 28 (55) 20 (69)/8 (36)* 3.89 (1.21–12.55)* 14 (64)/14 (48) 1.88 (0.60–5.83)
Mineralocorticoid receptor antagonist 7 (14) 7 (24)/0 (0)* — 6 (27)/1 (7)* 10.50 (1.16–95.17)*
Follow-up
Heart failure 25 (49) 24 (83)/1 (5)* 100.80 (10.89–933.19)* 21 (95)/4 (14)* 131.25 (13.6–1,266.37)*
NYHA functional class, none/1/2/3/4 26/13/6/6/0 5/12/6/6/0 / 21/1/0/0/0* 51.61 (5.55–479.79)* 1/10/5/6/0 / 25/3/1/0/0* 23.17 (4.36–123.12)*
Q-wave in electrocardiogram 11 (22) 11 (38)/0 (0)* — 10 (45)/1 (3)* 23.33 (2.68–203.14)*
Values are n (%), mean  SD, or median (interquartile range). *p < 0.05. †Deﬁned as: 1) heart failure; 2) life-threatening cardiac arrhythmia including complete atrioventricular block, sustained ventricular tachycardia; and/or cardiac arrest; 3) electrocardiogram and/or
laboratory evidence of myocardial damage; or 4) imaging evidence of myocardial and pericardial involvement, if non-vasculitis causes were excluded. ‡Deﬁned as nontreatment to overall disease duration ratio. §Expressed as equivalent of methylprednisolone.
ANCA ¼ antineutrophil cytoplasmic antibodies; CI ¼ conﬁdence interval; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New Your Heart Association functional class; OR ¼ odds ratio.
Letters
J
A
C
C
V
O
L
.
6
5
,
N
O
.
1
,
2
0
1
5
J
A
N
U
A
R
Y
6
/
1
3
,
2
0
1
5
:1
0
1
–
9
10
4
J A C C V O L . 6 5 , N O . 1 , 2 0 1 5 Letters
J A N U A R Y 6 / 1 3 , 2 0 1 5 : 1 0 1 – 9
105p ¼ 0.009), with shorter adverse cardiac event–free
survival (p ¼ 0.049 for log-rank test comparison).
At follow-up, linear regression revealed the asso-
ciation of LVEF with LVLGE volume (b ¼ 1.03;
p < 0.001) and LVLGE index (b ¼ 1.26; p < 0.001),
deﬁned as LVLGE volume to myocardial volume ra-
tio. In the subgroup of patients without cardiac in-
volvement at diagnosis, LVLGE was less frequently
observed in those with (n ¼ 13) than those without
(n ¼ 23) noncorticosteroid immunosuppression
initiated at diagnosis (1 [8%] vs. 15 [65%]; p ¼
0.001). Interestingly, LVEF was similar at the time of
diagnosis and follow-up (58.3  14.1% vs. 56.8 
14.2%; p ¼ 0.30) or decreased from the time of
diagnosis to follow-up (54.8  12.3% vs. 49.9 
17.7%; p ¼ 0.02) when noncorticosteroid immuno-
suppression was or was not introduced at diagnosis,
respectively.
Table 1 provides unadjusted association of base-
line and therapeutic data with LVLGE and LVEF <50%
at follow-up. Of baseline data, myocarditis (odds ratio
[OR]: 14.82; 95% conﬁdence interval [CI]: 1.75 to
125.73; p ¼ 0.01; chi-square: 10.4; area under the curve
[AUC]: 0.68) and LVEF <50% at diagnosis (OR: 13.50;
95% CI: 2.56 to 71.13; p ¼ 0.002; chi-square: 12.9;
AUC: 0.72) were the only independent determinants
of LVLGE and LVEF <50% at follow-up, respectively.
Importantly, noncorticosteroid immunosuppression
yielded an association with LVLGE and LVEF <50%
at follow-up (Table 1). Using sequential logistic
regression analysis for prediction of LVLGE and
LVEF <50% at follow-up, the lack of introduction of
noncorticosteroid immunosuppression at diagnosis
(chi-square: 24.8 and AUC: 0.83 for prediction
of LVLGE; chi-square: 23.3 and AUC: 0.84 for
prediction of LVEF <50%) and noncorticosteroid
immunosuppression discontinuity index, deﬁned as
nontreatment to overall disease duration ratio (chi-
square: 19.1 and AUC: 0.82 for prediction of LVLGE;
chi-square: 19.6 and AUC: 0.84 for prediction of LVEF
<50%), provided incremental prognostic value over
baseline data (all p < 0.05 for increase in global chi-
square and AUC of receiver-operating characteristics
between observed binary outcome and predicted
probabilities from regression models). The effect was
unchanged when data on standard treatment of heart
failure (i.e., use of angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, beta-
blockers, and mineralocorticoid receptor antagonists)
were included in the analysis. In addition, after
adjustment for age, number of relapses, and
maximum level of blood eosinophilia, the extent
of myocardial damage at follow-up expressed as
LVLGE volume was associated with duration ofnoncorticosteroid immunosuppression (b ¼ 0.28;
p ¼ 0.03) or noncorticosteroid immunosuppression
discontinuity index (b ¼ 0.13; p ¼ 0.008).
Accordingly, the data indicate that the lack of or
inadequate duration of noncorticosteroid immuno-
suppression appear to be independent determinants
of cardiac involvement in EGPA and the extent of
myocardial damage is associated with insufﬁcient
duration of noncorticosteroid immunosuppression.
We believe that noncorticosteroid immunosuppres-
sion has the potential to limit myocardial damage and
deterioration of LV systolic function and should be
regarded as an effective strategy for preventing heart
failure in patients with EGPA.*Tomasz Miszalski-Jamka, PhD
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26:16–23.Delegation of Duties and
Professional StandardsI read with interest the letter from Drew et al. (1),
which commented on the suspected shrinking pool of
cardiologists who are willing and able to read the
standard 12-lead electrocardiogram. They suggested
that nurse practitioners should be trained to perform
